Alnylam Pharmace. buy Subdi
Start price
10.09.18
/
50%
€98.87
Target price
12.09.18
€132.40
Performance (%)
-9.59%
End price
12.09.18
€89.39
Summary
This prediction ended on 12.09.18 with a price of €89.39. With a performance of -9.59%, the BUY prediction by Subdi finished with a loss. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -2.770% | -2.770% | 11.705% | 38.711% |
| iShares Core DAX® | 1.130% | 2.184% | 15.737% | 60.946% |
| iShares Nasdaq 100 | 1.128% | -0.611% | 7.324% | 94.649% |
| iShares Nikkei 225® | 2.610% | 4.958% | 20.446% | 48.989% |
| iShares S&P 500 | -0.006% | -0.952% | 2.166% | 60.348% |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von Subdi zu
Subdi stimmt am 10.09.2018 der Buy-Einschätzung von Subdi mit dem Kursziel 146,78$ zu.
Überschrift: Subdi stimmt der Buy-Einschätzung von stratec zu
(Vom Mitglied beendet)
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€70.57
27.10.18
27.10.18
€132.40
08.11.18
08.11.18
-6.88%
08.11.18
08.11.18
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€110.65
31.08.18
31.08.18
€132.40
06.09.18
06.09.18
-4.71%
06.09.18
06.09.18